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Abstract 
Hyaluronan (HA) is a glycosaminoglycan found in the extracellular matrices of epithelial and 
connective tissues. It has both structural and signalling functions, triggering various cell 
signalling cascades, which result in adhesion, migration and invasion. It has been reported 
that Squamous Cell Carcinomas (SCC) of the skin, oesophagus, larynx and lung, initially 
experience an increase in HA production. More advanced, less differentiated lesions are 
subject to decreased HA expression, which correlates with nodal involvement and 
metastasis in high-grade laryngeal and oral SCC. 
The first aim of this project was to determine the mechanism increasing HA synthesis by 
tumours, including which signalling pathways, Hyaluronan Synthase (HAS) enzymes and cell 
types are responsible. The second aim was to determine what consequences this has for 
different cells within the tumour in terms of phenotype. 
Epithelial and tumour-associated fibroblast cell lines from oral SCC were cultured in the 
presence of growth factors present in the tumour microenvironment (EGF, VEGF and TGF). 
Levels of HAS2/3 and HA production were measured using immunocytochemistry and a 
quantitative assay. HAS2 production was promoted in SCC epithelial cells, which 
corresponded with an increase in HA production. 
Regarding phenotype, the addition of HA had no effect on E-Cadherin expression, a marker 
of epithelial cells. However, it switched on vimentin expression, a marker of mesenchymal 
cells, in one well-differentiated SCC epithelial line but not in the other. 
These results suggest that increased HAS2 expression in transformed epithelial cells are 
responsible for the increase in HA, reported in SCC. Vimentin expression may indicate that 
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Epithelial to Mesenchymal Transition (EMT) is taking place, but this effect of HA may only 
occur in some SCC. Further research is needed to investigate this phenomenon. 
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Chapter 1 Introduction 
Aims and Objectives 
Squamous Cell Carcinoma (SCC) is by far the most 
common form of mouth cancer (Markopoulos AK, 2012). 
Unfortunately, it is becoming increasingly prevalent, 
particularly in young people, and is often detected late 
due to misdiagnosis and/or lack of symptoms, which has 
an adverse effect on prognosis (Markopoulos AK, 2012). 
Hyaluronan (HA) is a glycosaminoglycan found in the 
extracellular matrices of epithelial and connective tissues, 
with both structural and signalling functions. Oral SCC 
originates in the stratified squamous epithelium of oral 
mucosae, in which HA is normally abundant in the basal 
and spinous layers, but absent in the terminally 
differentiated layers (see Figure 1). 
It has been reported that SCC of the skin (Karvinen, 2003), 
oesophagus (Wang, 1996), larynx (Hirvikoski, 1999) and 
lung (Pirinen, 1998), initially experience an increase in HA 
production. More advanced, less differentiated lesions are subject to decreased and 
irregular HA expression. The reduced HA levels have been found to correlate with nodal 
involvement and metastasis in high-grade laryngeal and oral SCC (Hirvikoski, 1999) 
(Kosunen, 2004). 
A 
B 
C 
Figure 1. HA stain shows A) moderate 
levels of HA in the basal and spinous 
layers of untreated stratified 
squamous epithelium (keratinocyte 
culture), B) increased HA levels in EGF-
treated culture (20ng/ml) and C)  
decreased HA levels in TGFβ1 treated 
culture (4ng/ml) (Pasonen-Seppänen., 
2003). 
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The aim of this project is to investigate the induction of HA synthesis in tumours and the 
consequences this has on cell phenotypes.  Hanahan and Weinberg first emphasised the 
significance of ‘heterotypic signalling’ between normal stromal cells and the tumour cells 
(see Figure 2 (Hanahan D, 2000)). These interactions may take the form of growth factor 
production by stromal cells to facilitate tumour cell proliferation and Epithelial to 
Mesenchymal Transition (EMT), as well as tumour stroma formation and remodelling to 
facilitate tumour cell invasion and migration (Hanahan D, 2011). 
Since HA is also a stromal component, it is likely that it plays a role in such heterotypic 
interactions. In consideration of this, this project will include a tumour cell line of oral 
epithelial origin (TYS), two tumour-associated fibroblast cell lines (COMD) and a normal oral 
fibroblast cell line as a control (MM1). 
Areas of particular interest include which Hyaluronan Synthase (HAS) enzymes are 
responsible for the synthesis and consequent changes in HA levels, their differential 
regulation by growth factors and the different responses and consequent phenotypic 
changes in different cell types. To achieve this, the cell lines will be cultured in the presence 
of known HA-inducing growth factors and tested for HAS1/2/3 both qualitatively and 
quantitatively. The cells will also be tested for neoplastic markers, in particular motility and 
metastatic behaviours, since HA is known to be involved in tumorigenesis and motogenic 
activation (Ellis I, 2007). 
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Figure 2 Tumour biology must consider the cancer 
cells in relation to the normal cells also present in 
the tumour i.e. fibroblasts, endothelial cells. A) 
Cells present within a tumour (Hanahan D, 2000). 
B) Relationship between tumour-associated cells 
and their signalling pathways (Hanahan D, 2011). 
A 
B 
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Hyaluronan Structure 
Hyaluronan (HA) is an important and highly conserved glycosaminoglycan, ubiquitous in 
human tissues, with both structural and signalling roles. It is a polysaccharide chain of 
alternating N-acetylglucosamine (GlcNAc) and glucuronic acid (GlcA) units (See Figure 3; 
(Linker A, n.d.)). It is unusual amongst glycosaminoglycans as it is synthesised at the plasma 
membrane rather than the Golgi apparatus and is therefore directly extruded into the 
extracellular space without sulphation or any other modification (Prehm, 1984). Nuclear 
Magnetic Resonance (NMR) has been used to determine that HA is a twofold helix (Atkins E, 
1980), though at physiological pH in aqueous solution, the structure is likely to be locally 
dynamic and is now thought to form a fourfold helix on average (Almond A, 2006).  
Figure 3 A) Repeating unit of Hyaluronan. B) Putative Hyaluronan Synthase structure. C) Synthesis and 
extrusion of Hyaluronan at Hyaluronan Synthase enzymes at the plasma membrane. (Itano N, 2008) 
A 
B 
C 
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The structural significance of HA has long been appreciated due to its physical properties. 
Namely, it is deformable, has many negative charges along its length, attracting water 
molecules and ions, and can bind proteoglycans to form large macromolecules (Laurent TC, 
1995; Heinegard D, 1974).  This makes it an ideal space filling molecule, providing turgor 
pressure and a hydration buffer (Almond, 2007). However, it is now appreciated that HA has 
far more extensive roles in cell signalling and stromal regulation. 
Hyaluronan Receptors 
Hyaluronan receptors, also known as hyaladherins, may be found extracellularly, on cell 
surfaces or intracellularly (Evanko & Wight, 1999). Some of these are tissue specific while 
others are more widespread and may be upregulated or downregulated to control various 
physiological processes. 
The Hyaluronan receptors LYVE-1, Stabilins and CD44, all contain a ‘Link‘module for binding 
HA (Kohda, 1996). In contrast, RHAMM contains the B(X7)B motif (also found in the Link 
module) in a much shorter sequence (Yang, 1994). Some of the functions of these receptors 
are shown in Table 1. 
CD44 is the principal HA receptor found ubiquitously. It is classed as an itinerant hyaladherin 
as it is found both extracellularly and intracellularly. It may be considered as three major 
domains: an N-terminal HA binding domain, a variable middle domain and a cytoplasmic 
domain interacting with the cytoskeleton (Underhill, 1992). CD44 isoforms vary due to 
alternative splicing and post-translational modifications. The expression patterns of some of 
these are shown in Table 2. However, some isoforms are associated specifically with tumour 
cells and tumour progression (Wang, 2009). These are CD44v3, CD44v6 and CD44v10 and 
their nomenclature is derived from the variable exons they include (see Figure 4). 
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RHAMM (also designated CD168) is another itinerant hyaladherin and is also alternatively 
spliced but to a lesser extent (Turley, 2002; Turley E, n.d.). The truncated form is expressed 
specifically in response to injury, in tumour cells and in some Ras-transformed cell lines 
(Turley, 2002; Slevin, 2007). 
Although the majority of HA binding proteins are membrane-bound receptors, some HA-
binding proteins are released into the Extracellular Matrix (ECM), in particular CD44 
(Knudson C, 1993; Day A, 2002). These are responsible for binding and organising stromal 
molecules. 
  
Figure 4 Exon map of CD44 gene. Note the 10 variable exons that may be alternatively spliced into variant 
forms. (Wang, 2009) 
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Isoform Structural 
Characteristic 
Location Relative 
Amount 
CD44H Most common form, 
core protein, 37 kDa 
Haemopoietic cells, leucocytes 
and other mesodermal cells 
Major 
CD44TR Lacks cytoplasmic 
domain 
Haemopoietic  and other cell 
lines 
Minor 
CD44E (R1) 132 amino acid insert in 
middle domain 
Epitheilia and other cells Major 
CD44E (R2) 69 amino acid insert in 
middle domain 
Epithelia, granulocytes and 
mononuclear cells 
Minor 
CD44M 162 amino acid insert in 
middle domain 
Malignant rat tumour cell lines Unknown 
Table 2. CD44 Isoforms and their expression patterns. Adapted from (Underhill, 1992) 
HA Receptor Associated Roles 
CD44 Attachment and Organisation of ECM (Day A, 2002) 
Cluster to attract and stimulate migration of lymphocytes during 
inflammation (Salmi, 2013) 
Cell Aggregation (Zawaideh, 1996) and Proliferation (Meran, 2011; Takano, 
2009) 
Angiogenesis (Cao, 2006) 
RHAMM Co-receptor for integral membrane proteins 
Cytoskeleton remodelling for motility (Assmann, 1999) 
Progression past G2M boundary of cell cycle for proliferation (Assmann, 
1999) 
LYVE-1 Lymph specific receptor  with uncertain function (Johnson, 2007); possibly 
HA metabolism under inflammatory conditions or cell migration 
Role in tumour cell adhesion (Du, 2013) 
Stabilin-1 HA scavenging and regulation of cell secretory processes (Kzhyshkowska, 
2006) 
Stabilin-2 HA scavenging in the liver (Falkowski, 2003) 
Adhesion and homing of stem cells to bone marrow (Qian, 2009) 
Table 1. Roles of HA Receptors reported in the literature 
19 
 
 
Hyaluronan Signalling Pathways and Functions 
Even nanogram quantities of HA have been shown to produce significant effects on cell 
signalling pathways and metabolism (Turley, 2002). To achieve this, CD44 and RHAMM 
interact with various kinase pathways as well as directly binding cytoskeleton molecules. 
The signalling molecules activated by CD44 are summarised in figure 5A. Cell growth is 
mediated by the tyrosine kinase p185HER2 (Bourgignon, 1997), a known oncogene product. 
Cell migration is mediated by the tyrosine kinase C-Src, which phosphorylates the 
cytoskeletal protein cortactin to promote polymerisation and rearrangement of actin 
(Bourgignon, 2001). CD44 signalling is also mediated by Rho-like GTPases, which stimulate 
Rho Kinase (ROK) to phosphorylate several proteins including CD44 itself. This modification 
promotes CD44 binding to ankyrin, a cytoskeletal protein that links plasma membrane 
structures to the cytoskeleton. Ankyrin induces cytoskeleton activation as well as aiding 
presentation of CD44 on the plasma membrane for HA binding, promoting positive feedback 
(Turley, 2002). It stimulates the release of intracellular Ca2+stores, promoting contraction 
and consequent cell motility (Wang S, 2006). It also induces degradation of the ECM to 
facilitate migration/invasion (Wang S, 1998). Rac1 is activated in a further signalling 
pathway, associated with membrane ruffling and projections for motility (Bourgignon, 
2000).  
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Large HA chains induce quiescence and contact inhibition of cell division via CD44 and the 
intracellular protein Merlin (Morrison., 2001). They also suppress apoptosis (Jiang., 2005) 
via NF-κB to maintain epithelial integrity. 
  
Figure 5 A) Signalling pathways 
associated with activation of CD44 and 
tumorigenesis B) Signalling pathway 
linking activation of RHAMM with 
microtubule remodelling and 
migration. Sourced from (Turley, 2002) 
A 
B 
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At the cell membrane, RHAMM acts as a co-receptor whose signalling is mediated by 
tyrosine and serine/threonine kinases (see Figure 3B). Associated tyrosine kinases include 
Src, Focal Adhesion Kinase (FAK), Erk and protein kinase C (PKC). Src and FAK phosphorylate 
cytoskeleton proteins such as cortactin and paxillin to promote rearrangement of actin and 
turnover of lamellae focal adhesions (Hall, 1996). RHAMM interacts with the Ras GTPase 
both at the cell surface and intracellularly (Hall, 1995).  Intracellular RHAMM can associate 
with kinases, calmodulin (Lynn B, 2001) and both the actin cytoskeleton and microtubules 
(Assmann, 1999). In this way it links kinase pathways and directly stimulates cytoskeleton 
rearrangements. Interestingly it also has a role in regulating the mitotic spindle and 
promoting cell cycle progression past the G2M checkpoint (Assmann, 1999). 
It would seem that HA signalling can have contradictory effects, both inhibiting and 
promoting cell cycle progression through different pathways. However, these pathways are 
not active simultaneously and are activated by HA molecules of different sizes. High 
molecular weight HA promotes cell integrity and impedes differentiation while low 
molecular weight HA, fragmented by hyaluronidases or oxidation by free radicals, activates 
signalling pathways and gene expression resulting in inflammatory responses, cell 
proliferation and migration. Tables 3 and 4 list some of the signalling pathways and effects 
stimulated by HA of different lengths. 
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Molecular size 
(saccharides) 
Signalling molecules 
~4 IL-12, TNFα 
Up-regulation of Fas expression 
4 Erk,  JNK, p38 stimulation 
6 Activation of NF-κB in chondrocytes 
~12 Up-regulation of PTEN in tumour cells 
6-20 Inhibition of anchorage-independent growth through 
suppression of PI 3 kinase 
~34 FAK, PI 3 kinase 
Not determined Activation of NF-κB 
Table 3. Differential signalling by HA fragments of different lengths. Adapted from (Stern R, 
2006) 
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Size (saccharides) Function 
 
High-molecular-mass 
HA>1000-5000 
Suppression of angiogenesis 
Immune suppression 
Inhibition of phagocytosis 
Suppression of HA synthesis 
HA fragments 
 
~1000 
Induction of inflammatory chemokines 
Stimulation of PAI-1 
Stimulation of urokinase 
10-40 Induction of CD44 cleavage 
Promotion of tumour cell migration 
8-32 Stimulation of angiogenesis 
Stimulation of tumour neovascularization 
~15 Suppression of smooth muscle cell proliferation 
12 Endothelial cell differentiation 
Up-regulation of PTEN in tumour cells 
10 Displacement of matrix HA on oocyte surface 
Displacement of proteoglycans from cell surface 
 
6 
Suppression of HA cable formation 
Induction of NO and MMPs in chondrocytes 
Induction of HAS2 in chondrocytes 
4-6 Induction of cytokine synthesis in dendritic cells 
Transcription of MMPs 
 
 
4 
Up-regulation of Hsp 72 expression 
Suppression of apoptosis 
Induction of chemotaxis 
Up-regulation of heat shock factor-1 
Up-regulation of Fas expression 
Suppression of proteoglycan sulphation 
Table 4. HA chain sizes and their associated functions (partial list). Adapted from (Stern R, 
2006). 
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At the tissue level, large HA chains are space filling, anti-angiogenic (Deed, 1997), 
immunosuppressive and maintain stability. Conversely, smaller HA fragments are 
inflammatory, angiogenic (Deed, 1997) and immune-stimulatory. Immunosuppression is 
facilitated by the ability of high molecular weight HA to bind and coat cell surfaces, blocking 
ligands from binding surface receptors. Small HA fragments may be the product of 
degradation in pathological conditions (See “Hyaluronan Synthesis and Degradation”) or 
they can come from a bacterial source (for example, Streptococci). It is therefore beneficial 
that they stimulate an immune response, binding Toll-like Receptors 2 and 4 (TLR2/4) on 
dendritic cells to stimulate maturation and consequent activation of T lymphocytes (Jiang, 
2005). 
 There are problems with studying smaller HA chains (reviewed in (Turley, 2002)), including 
the risk of contamination and difficulties in accurately determining their size. However, the 
general trend reflects this divide between large HA maintaining homeostasis of the ECM and 
small HA inducing stress responses. 
HA signalling has incredibly diverse roles in different tissues. For example, in the embryo, it 
is responsible for Epithelial to Mesenchymal Transition (EMT) (Camenisch, 2000) and many 
organogenesis processes. It is particularly crucial to chondrogenesis (Ohno, 2005). In adults, 
HA signalling is intrinsic to wound healing, inflammation and stromal organisation/re-
organisation.  
Wound healing is an excellent example of differential signalling by large and small HA 
molecules. Initially, there is an increase in local HA due to impaired drainage. These large HA 
molecules bind fibrinogen, stimulating local clot formation (Frost S, 1990). HA is later 
cleaved by Hyaluronidase enzymes (Hyals) and free radicals. The consequent small HA 
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molecules stimulate inflammation, immune reactions and angiogenesis, contributing to the 
ECM remodelling required in wound healing. 
Hyaluronan and Tumour Cells 
Tumour cells manipulate HA signalling pathways to induce many processes useful to their 
growth, survival and spread (i.e. proliferation, angiogenesis, and migration). By expressing 
specific variant forms of HA receptors, those signalling pathways favouring tumorigenesis 
can be promoted (see Table 5). 
Certain HA oligosaccharides induce the cleavage and release of the extracytoplasmic domain 
of CD44 from the cell membrane. It is thought that providing this source of freely circulating 
CD44 fragments to higher grade tumour cells allows them to become independent of CD44-
mediated regulation (Suguhara, 2003). 
 
CD44 
Variant 
 
Differential 
Associations 
 
Effect 
Increased 
Cell 
Proliferation? 
Increased 
Cell 
Migration? 
CD44v3 VEGF Angiogenesis N Y 
Matrix Metalloproteinases 
(e.g. MMP-9) 
ECM degradation 
for migration 
CD44v6 MAP Kinase and Ras 
signalling 
Proliferation Y N 
CD44v10 Reduced affinity for HA for 
constitutive activation of 
CD44-cytoskeleton 
interactions 
Cell motility Y Y 
Table 5. Tumour specific variants of CD44 and their tumorigenic effects. Adapted from 
(Wang, 2009) 
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HA-CD44 interactions may also play a role in chemotherapy resistance. CD44 physically 
associates with the EGF receptor (EGFR), which is known to mediate oncogenic signalling 
and is a target of the chemotherapy drugs cisplatin, methotrexate and adriamycin. It has 
been shown that HA promotes CD44-EGFR association, EGFR activation and subsequent 
ERK1 and ERK2 phosphorylation (Wang S, 2006). 
Hyaluronan Synthesis and Degradation 
 Three mammalian Hyaluronan Synthases (HAS) have been documented (Itano N, 2008), 
which synthesise HA chains by alternate addition of saccharides (See Figure 3; (Prehm, 
1983)). They consist of a large central domain, making up 54-56% of the total protein, and 
clusters of transmembrane or membrane-associated domains.  The central domain is 
thought to contain the catalytic regions though six discrete activities may be identified 
within the enzyme (Weigel PH, 2007). These include binding sites and glycosyltransferases 
for both GlcNAc and GlcA, a binding site for the growing HA chain and a transfer module for 
its extrusion.  
Since chain length seems to be such a crucial factor in HA signalling, it is interesting to note 
that the different HAS proteins produce different length HA chains (Weigel P, 1997). HAS3 
produces chains of 1 x106Da while HAS1 and HAS2 produce longer chains of 2 x105 – 2 x106 
Da. It is also significant that the HAS proteins have different expression patterns. HAS1 is 
predominant in adults while HAS2 is the most significant in embryos (Tien JY, 2005). HAS3 is 
highly expressed in areas of inflammation and in tumour cells, which reflects the 
inflammatory role of shorter HA fragments (Tammi, 2011). 
 The dynamic nature of HA signalling makes turnover very important and actually reaches 
approximately 15g per day in humans (Laurent U, 1991). Turnover occurs at three levels. 
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Locally, cells bind, internalise and degrade HA. Stern et al. have produced a catabolic 
scheme in which HA is cleaved by successive hyaluronidase (Hyal) enzymes (Stern R, 2006). 
Hyal2 is a surface receptor, which makes the initial cleavage. These fragments are taken up 
by the cell in endosomes and delivered to acidic lysosomes where Hyal1 further degrades 
them to tetrasaccharides. At tissue level, HA is bound by the lymphatic vessel endothelial 
cell receptor LYVE-1 and delivered via lymphatic drainage and vasculature to the liver 
(Prevo, 2001). Here it is internalised by hepatocytes with the help of Stabilin-2 receptors and 
degraded by tissue-specific hyaluronidases (Weigel, 2003). Lastly, HA is degraded by free 
radicals under oxidative conditions, directly or indirectly in coordination with Hyals 
(Monzon, 2010; Soltes, 2006).  
Regulation of Hyaluronan Levels 
Transcription of the HAS genes and consequent HAS synthesis are the major regulatory 
systems of HA levels (Tammi, 2011). The three HAS genes are regulated differentially by 
many growth factors. For example, Transforming Growth Factor β1 (TGFβ1) upregulates 
HAS1 expression while downregulating HAS2 and HAS3 (Oguchi T, 2004; Pasonen-
Seppänen., 2003). Table 6 includes some of the reported effects of growth factors on HAS 
expression in different cell cultures. Although these data must be considered in context of 
the tissue cultures used, any of these signalling pathways could apply in more advanced, 
poorly differentiated tumours. 
Other regulators of HAS transcription include corticosteroids (such as dexamethasone), 
which significantly downregulate HAS (Zhang, 2000), retinoic acid, which induces HAS3 (Sayo 
T, 2013), and substrate concentrations, specifically UDP-GlcNAc (Jokela, 2011). 
28 
 
So far only transcriptional regulators have been named but growth factors also regulate HAS 
at a post-transcriptional level. All three HAS enzymes increase their activity when 
phosphorylated (Klewes L, 2010). This is associated with the activation of Erb-
B2/extracellular signal-related kinase and the growth factors EGF, Platelet-Derived Growth 
Factor (PDGF) and IL-1β. Also, monoubiquitination of Lys190 is essential for HAS activity 
(Karousou, 2010). 
Another possible stage in HAS activation may be dimerisation. It has been demonstrated 
that HAS2 and HAS3 can form homodimers and heterodimers (Karousou, 2010) and it has 
even been proposed that HAS enzymes could form part of larger multimeric complexes. 
However, there is little evidence for this.  
Finally, recent work has revealed two antisense RNA molecules, named HAS2 AS1 and HAS2 
AS2, which contribute to regulation of HAS synthesis in vitro (Chao H, 2005) and is likely to 
similarly decrease HAS synthesis in vivo. It is complementary to the first exon of HAS2 
mRNA, including the transcription and translation initiation sites. Binding of the HAS2 and 
HAS AS1 mRNA not only blocks these processes but also targets the strand for degradation. 
It is therefore a rapid and effective mechanism for arresting HAS synthesis.  
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Growth 
Factor 
Effect on Has 
Expression  
Context of Interactions 
HAS1 HAS2 HAS3 
TGFβ1 ↑ ↓ ↓ Synovial fibroblasts, Organotypic 
keratinocytes, Mesothelial cells 
EGF  ↑ ↑ Synovial fibroblasts, Organotypic 
keratinocytes,  
PDGF ↑ ↑ ↑ Mesothelial cells 
FGF-2 ↑ ↑ ↑ Periodontal Ligament fibroblasts (during 
inflammation) 
IL-1β ↑ ↑ ↑ Synovial fibroblasts, Skin fibroblasts  
TNFα ↑ ↑ ↑ Synovial fibroblasts, Skin fibroblasts 
Table 6. Some known growth factor effects on Has expression from sources (Pasonen-
Seppänen., 2003; Oguchi T, 2004; Tammi, 2011; Jacobson A, 2000; Shimabukuro, 
2011; Campo G, 2006). Key: ↑Upregulated; ↓Downregulated 
 
Possible Growth Factors Present in the Tumour Microenvironment 
Transforming Growth Factor β (TGFβ1)  
The TGFβ superfamily consists of several structurally and functionally linked growth factors, 
expressed in many embryo and adult tissues. Regulation of TGFβ activity occurs by 
regulation of TGFβ gene transcription, the need for activation of TGFβ and sequestration of 
activated TGFβ by the ECM (Massague, 1990). Cell responses to TGFβ depend on the cell 
type and presence of other growth factors, but TGFβ is associated with the regulation of 
many cell processes such as proliferation, migration, apoptosis, adhesion and angiogenesis 
(Jakowlew, 2006). TGFβ signalling operates predominantly via SMAD pathways (Derynck R, 
2003). Ligand binding causes the two TGFβ receptors to form a complex with 
serine/threonine kinase activity. This differentially activates members of the R-SMAD 
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second messenger family, which bind the Co-SMAD (SMAD4) to translocate to the nucleus 
and interact with co-activators or co-repressors of gene expression. A simplified version of 
SMAD-mediated signalling is given in Figure 6. However, members of the SMAD pathway 
interact with other signalling molecules. 
It was initially thought TGFβ would act simply as a tumour suppressor due to its autocrine 
promotion of cell cycle arrest and apoptosis in epithelial tissues (Arteaga C, 1990). There is 
now evidence for TGFβ as both a tumour suppressor and pro-oncogenic factor. TGFβ and 
SMADs interact with proteins directly involved in regulating the cell cycle such as Cyclin 
Dependent Kinases (CDKs) and can induce the synthesis of cyclins (Jakowlew, 2006).  In 
many cancers, the TGFβ gene has been found to be mutated or the TGFβ receptor has been 
defective (Jakowlew, 2006). In this way, tumour cells can escape regulation by TGFβ and 
continue to proliferate uninhibited. Mutations of SMAD4 have also been associated with the 
progression of colorectal cancer (Xu, 2000) and the constitutive phosphorylation of SMAD2 
is associated with poor prognosis of HNSCC (Xie, 2003). It is thought that SMAD4 exerts its 
own tumour-suppressor effect by inhibiting Ras-dependent Erk (Extracellular signal 
Regulated Kinase) signalling (Iglesias, 2000). When SMAD4 is inactivated, Erk signalling may 
become excessive and contribute to tumour progression. 
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The absence or alteration of TGFβ signalling may help to initiate tumorigenesis, but the 
presence of TGFβ signalling later takes on a pro-oncogenic role. It plays a role in stromal 
regulation, immune suppression and angiogenesis (Jakowlew, 2006), although its role in 
angiogenesis is likely to be indirect via induction of VEGF (Pertovaara, 1994). It may also 
induce Epithelial to Mesenchymal Transition (EMT) though only if the Erk pathway is also 
activated (Xie, 2004). 
 
Figure 6 A) Generalised signal 
transduction pathway from 
extracellular ligand binding at the 
receptor to altered gene expression 
via the Smad pathway (Wrana et al, 
2000). B) Heteromeric TGFβ receptor 
combinations and their R-Smad 
targets (Wrana et al, 2000). 
A 
B 
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Epidermal Growth Factor (EGF) 
The Epidermal Growth Factor-like molecules, including TGFα, amphiregulin and of course 
EGF itself, are encoded by separate genes and are produced for both paracrine and 
autocrine signalling. This family is characterised by their ability to bind the EGF receptor 
(EGFR) and induce a mitogenic response, and a motif of six half-cysteine residues (XnCX7CX2-
3GXCX10-13CXCX3YXGXRCX4LXn) (Carpenter G, 1990). The EGF receptor family, also known as 
ErbB, consists of an extracellular ligand binding domain, a single hydrophobic anchor and 
tyrosine kinase cytoplasmic domain, and is similar in structure to the receptors for PDGF, 
FGF and Insulin-like Growth Factors (IGF) (Carpenter G, 1990). Their cytoplasmic tyrosine 
kinase domains are similar to that of many oncogene products. They activate multiple 
signalling cascades including the Phosphoinositide 3-Kinase (PI3K) pathway, RAS/ERK 
pathway and JAK/STAT pathway (see Figure 7). These leads to the activation of kinases, 
which can inactivate pro-apoptotic proteins, and transcription factors such as Nuclear 
Factor-κB  (NF-κB) and STAT, which translocate to the nucleus to activate anti-apoptotic and 
cell-proliferative genes (Sethi G, 2007). HAS2 and HAS3 are also upregulated by EGF (Chow 
G, 2010). 
Increased expression of EGFR and/or its ligands is a feature of most carcinomas (Zhang X, 
2012; Baselga J, 2005) and some carcinoma EGFR have been found to gain ligand-
independent activity (Sethi G, 2007). Overexpression of EGFR in oral cancers has been 
associated with malignancy and poor prognosis (Ribeiro, et al., 2014). Since EGFR signalling 
is known to be such a significant contributor to tumour initiation and progression, it is the 
target of many cancer therapies in the form of monoclonal antibodies, which bind EGFR, or 
protein kinase inhibitors (Zhang X, 2012). 
33 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 A) EGFR signalling pathways including the Phosphoinositide 3-Kinase Pathway (green), RAS/ERK 
pathway (red) and JAK/STAT pathway (yellow). These activate various anti-apoptotic proteins (white) and inactivate 
pro-apoptotic proteins (black). B) Targets of current cancer therapies (Henson E, 2006) 
A 
B 
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Fibroblast Growth Factor -2 (FGF-2) 
FGF2 is a polypeptide growth factor with unconventional secretory protein as it can bind 
PI(4,5)P2 directly and thereby translocate plasma membranes without the need for 
intracellular, membrane-bound intermediate vesicles (Nickel, 2011). FGF is involved in 
diverse processes including neurotrophic activity, lymphangiogenesis, stem cell 
differentiation, osteogenesis and tumour cell migration and invasion (Wu X, 2003). 
There are 22 FGFs but the communication from stromal cells to epithelial cells is mediated 
by stromal FGF7/FGF10 and epithelial FGF2. The angiogenic effect of FGF2 is synergistic with 
signalling by PDGF-BB and VEGF (Zhang X, 2012). The receptors for PDGF (PDGFRα and 
PDGFRβ) are upregulated in endothelial cells in the presence of FGF-2 signalling (Cao Y, 
2008). Also, PDGF-BB is able to induce FGFR-1 in vascular smooth muscle cells and sensitise 
them to FGF-2 (Cao Y, 2008). Regarding VEGF, the synergistic relationship takes a simpler 
form in that both signalling pathways involve the activation of Src tyrosine kinases. These 
activate focal adhesion kinase (FAK) and subsequently Mitogen-activated protein kinase 
(MAPK), which leads to reorganisation of the cytoskeleton actin and cell motility (Yan W, 
2008). 
Platelet-Derived Growth Factor (PDGF) 
The PDGF family are the homo or heterodimers: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC and 
PDGF-DD. They are bound by the receptors PDGFR-α (except PDGF-DD) and PDGFR-β (only 
PDGF-BB and PDGF-DD) (Heldin C, 2002). PDGFR-α is expressed during early embryonic 
development whereas PDGFR-β is expressed by mesenchymal cells and is upregulated 
during wound healing. Both receptors may therefore be of interest in tumour cells, which 
share characteristics with each of these cell types. 
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The activation of PDGFR results in homodimerisation and tyrosine kinase domain activation, 
which leads to activation of Src, PI3K, AKT, Ras and ERK pathways (Taylor, 2000). These are 
known to promote cell survival and proliferation. 
Vascular Endothelial Growth Factor (VEGF) 
VEGF is a family of five soluble heparin-binding polypeptide growth factors, promoting 
endothelial cell migration (Ferrara, 2009). Although there is no literature regarding the 
effect of VEGF on HAS expression, it is another growth factor that is present in the tumour 
microenvironment. VEGFs act on three receptors (VEGFRs) with tyrosine kinase activity 
(Koch S, 2012). In general VEGFR1 is expressed in monocytes and macrophages, VEGFR2 is 
expressed in vascular endothelial cells and VEGFR3 is expressed in lymphatic endothelial 
cells. The VEGFs are responsible for regulating endothelial cell migration, proliferation and 
consequent lymphangiogenesis through activation of pathways such as RAS/RAF/ERK/MAPK 
and PI3K/PDK/AKT (Koch S, 2012). VEGF-C has been shown to promote lymphangiogenesis 
in tumours and subsequent dissemination and metastasis in lymph nodes (Mandriota, 
2001). 
There is little information in the literature describing VEGF signalling in tumour progression. 
However, recent work has demonstrated that VEGF can increase motility in oral SCC cells in 
vitro via phosphorylation of the Akt pathway (Islam, et al., 2014). 
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Chapter 2 Materials and Methods 
Cell Culture 
MM1 cells are gingival fibroblasts provided by Dr M. Macluskey of Dundee Dental 
Hospital. COMD11, COMD24 and COMD25 cells are tumour-associated fibroblasts from oral 
squamous cell carcinoma (SCC) biopsies, donated by the Oral Surgery Clinic, Ninewells 
Hospital, Dundee, and isolated from explant cultures in Dundee Dental School. HaCaT cells 
are commercially available human spontaneously immortalised epidermal keratinocytes 
(Life Technologies), donated by Prof S Schor. These are used as a control cell line for the SCC 
cell lines, PM1, TYS and TR146. PM1 cells are taken from a dysplastic lesion from the 
forehead skin, donated by Dr D Crouch, Dundee Dental School. TR146 are a commercially 
available cell line taken from the lymph node of a patient with a well-differentiated SCC of 
the oral mucosa (Sigma Aldrich). TYS are taken from an oral adenoid SCC, derived from a 
minor salivary gland and donated by Dr K Harada, University of Tokushima, Japan. All 
samples were collected after receipt of ethical approval. 
Cells to be stained were grown on 60 mm dishes in 10% (v/v) Foetal Calf Serum medium 
(FCS-MEM; see Appendix 1 for recipe) supplemented with 1% (v/v) glutamine until they 
reached their maximum confluency. However, not all cell lines became 100% confluent 
before detaching from the plate, so in these cases, their maximum confluency was 
approximated. They were then incubated with growth factors for 24 hours. TGFα (10-1033-
B, Insight Biotechnology) or VEGF121 (10-1296-B, Insight Biotechnology) were added at 
concentrations of 1pg/ml, 10 pg/ml, 100 pg/ml and 1ng/ml, whereas EGF (10-1001-B, 
Insight Biotechnology) was added at concentrations of 10pg/ml, 100pg/ml, 1ng/ml and 
10ng/ml. HA (HA2002, Fermentech) was added at concentrations from 10ng to 10μg. 
Samples were then prepared as appropriate to their use. 
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Immunocytochemistry (ICC) 
The cells were fixed in methanol for 20 minutes, and incubated in 1.0% (v/v) Triton x100 
detergent in PBS for 5 minutes before beginning the ICC protocol. Firstly, the cells were 
incubated in 5% (v/v) Normal Goat Serum (NGS) in PBS-T for 30-60 minutes. The cells were 
then incubated with the primary antibody (see Appendix 2) overnight in a humidified 
chamber at 4˚C. It was found that staining worked best at a dilution of 1:50 (v/v) HAS2 
antibody in 5% NGS in PBS-T. Next the cells were incubated with the secondary antibody for 
60-120 minutes. The secondary antibody was an anti-rabbit IgG conjugated with a 
fluorescent dye at 1:1000 (v/v) in 5% NGS in PBS-T. The fluorescent dye could then be 
detected with a UV fluorescence microscope with a light source and an inverted phase 
contrast microscope (Olympus IX70). Images were captured with Metamorph software and 
a 10 second exposure. 
Statistical Analysis of ICC 
Fluorescence intensity was calculated using ImageJ software (Research Services Branch, 
National Institute of Health). Due to the varied cell confluency and frequency between 
plates, five cells were selected in each photo and their fluorescence intensity recorded. The 
selection favoured cells that were free from overlap and artefact so that the final average 
taken would represent an average fluorescence per cell. Only five cells were selected as 
some fibroblast samples had only four or five cells in a photo. Three samples of background 
fluorescence were taken in each photo to determine an average to subtract from the cell 
data. The formula used to give the Corrected Total Cell Fluorescence (CTCF) can be found in 
Appendix 3. 
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The CTCF of each sample was normalised within each experiment (constant cell type, 
varied growth factor concentration) by dividing by the mean of all the CTCFs in the 
experiment. A Pearson’s Correlation Coefficient was determined for each experiment to 
identify correlations. With a P value of 0.05, the critical value for r = 0.878. However, where 
r > 0.5, a correlation may be considered reasonably strong although it is not statistically 
significant.  
HA ELISA Assay 
Cells were incubated with the growth factors EGF or VEGF for 24 or 48 hours. The 
collection media were then centrifuged and decanted to remove any cells and frozen.The 
DuoSet Assay Development kit for hyaluronan from R and D Systems (Cat No DY3614) was 
used according to manufacturer’s instructions. 
96-well plates were used and incubated with capture reagent overnight (all materials can 
be found in Appendix 4). The plates were blocked and filled with the samples, diluted in 
reagent diluent. In order to create a standard curve of optical densities against HA 
concentration, a HA standard was diluted to concentrations from 30ng/ml to 0.123ng/ml 
and included in every plate. The samples were incubated at room temperature for 2 hours. 
The plates were subsequently incubated with the detection reagent for 2 hours, then 
Streptavidin-HRP (1:2000) for 20 minutes, the substrate solution for 20 minutes and finally 
the stop solution was added. The optical densities of the samples were then read at 450nm 
and 570 nm and analysed using the FLUOstar OPTIMA (BMG Labtech) system. The results 
were then exported to Microsoft Excel for analysis and creation of a standard curve. 
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SDS PAGE and Western Blot 
Samples were prepared from cells lysed in situ with RIPA buffer and Protease Inhibitors 
(Ref 11836170001 Roche). Samples contained equal volumes of cell lysate and Laemmli 
loading buffer with 5% v/v 2-mercaptoethanol (#161-0737 Bio-Rad), and were heated at 
95˚C for 5 minutes before being loaded onto a 10% BioRad TGX Gel. Gels also contained a 
sample of Magicmark XP molecular weight markers (LC5603 Invitrogen). 
The gels were run according to the manufacturer’s instructions with TGS running buffer 
(See Appendix 2 for all buffer recipes) then blotted (semi-dry 15V 42 minutes) onto 
nitrocellulose membranes using Towbin transfer buffer (68) and blocked using 1% (w/v) fat 
free milk TBST. They were then incubated with primary rabbit antibodies for vimentin 
(#3932 Cell Signaling; diluted 1:2000 in 1% (w/v) Milk TBST) and E-Cadherin (#3195S Cell 
Signaling; diluted 1:1000 in 1% (w/v) Milk TBST) overnight with orbital shaking. The 
following day, the blots were washed with TBST three times for 20 minutes with orbital 
shaking and incubated with a goat anti-rabbit secondary antibody (#7074 Cell Signaling) 
diluted 1:2,000 in 1% (w/v) milk TBST, for an hour. The TBST washes were then repeated 
before adding 0.7ml of Immun-Star Western C substrate (BioRad), which displays 
chemiluminescence in the presence of Horse Radish Peroxidase (HRP), attached to the 
secondary antibody. This was detected by a Biorad ChemiDoc MP Imaging System. Imagelab 
software was used to analyse the visualised blots. 
Scratch Assay 
The cells were cultured until confluent and incubated with SF-MEM for 24 hours before 
the scratch was carried out. A flexible pipette tip was used to ‘scratch’ a line down the 
monolayer of cells without scoring the plastic of the dish. Pictures were taken at this point 
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as a starting time point (t0). The cells were then incubated with HA at concentrations from 
10ng to 10 μg with a SF-MEM negative control. The dishes were checked at 3 hours, 6 hours 
and 24 hours for changes and further photos were taken if changes had occurred. 
 
Boyden Chamber Assay 
The cell samples were passaged the day before harvesting and on the day of harvesting, as it 
has been shown in our lab that confluent cells are less suitable for this assay. This assay 
follows the technique used by Schor et al., 1996, 1999, 2006. 
Polyvinylpropylene-free polycarbonate Nucleopore membranes (Fisher 8.0µm pore) were 
coated with native type I collagen by overnight immersion in a 100µg/ml aqueous solution 
at 4oC and air dried before being fitted into a 48-well microchemotaxis chamber 
(Neuroprobe Inc). The lower wells contained the indicated peptide fragment in serum free 
(SF-MEM) plus 2µg/ml bovine serum albumin (BSA) in assays designed to measure 
chemotaxis. A total of 12.5x104 cells suspended in 50µl SF-MEM + 2µg/ml BSA were then 
plated into the upper wells. The chambers were incubated for 5-6 hours at 37oC in a 
humidified CO2 incubator and the membranes then removed, fixed in methanol and stained 
with Mayers Haemotoxylin. Cells remaining on the top of the membrane were removed, the 
membranes mounted onto glass slides and examined under bright field illumination at a 
magnification of 200x. The number of migrated cells adherent to the lower surface of the 
membrane were counted in three fields per well and 6 wells per variable (i.e. 18 fields per 
variable). Data are expressed as mean cell number and standard error per field. 
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Chapter 3 Results 
HAS2 and HAS3 Levels in Fibroblast and Epithelial Cells by 
Immunocytochemistry 
This experiment used three epithelial cell lines from Squamous Cell Carcinomas (PM1, 
TR146, TYS) and one normal epithelial control (HACAT), as well as three tumour-associated 
fibroblast lines (COMD11, COMD24, COMD25) and one normal fibroblast control (MM1). 
The cell lines were grown until at least 80% confluency before a 24 hour incubation with 
either EGF, TGFβ1 or VEGF over a range of concentrations. The cells were then fixed in 
methanol and an immunohistochemical (ICC) staining procedure was used for HAS2 and 
HAS3. The secondary antibody was linked to an Alexa Fluor dye for detection with 
fluorescence microscopy. In this way, HAS2 and HAS3 localisation was viewed as well as 
quantified by analysis of fluorescence intensity using ImageJ. 
The data were normalised separately within their experimental runs, giving two sets of data 
(“Normalised 1” and “Normalised 2”).  From these data, the Pearson’s Correlation 
Coefficient (r) was calculated to determine linear correlations. These r values are given in 
Table 7.  
HAS2 and HAS3 Distribution and Localisation 
Of the HAS isoforms, HAS1 is usually found in adults whereas HAS2 and HAS3 are found 
during inflammation or in embryological development. However, in the cell lines tested, the 
presence of HAS2 and HAS3 was almost ubiquitous. In the majority of samples, 100% of cells 
stained for HAS2 and HAS3. 
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  ICC showed HAS2 and HAS3 were present evenly throughout the cells, which is to be 
expected since it is a plasma membrane protein. In some fibroblast photos, it seems as if the 
stain is more concentrated over the nucleus (See Figure 8). However, this is most likely due 
to the elongated fibroblast shape with a thick cell body surrounded by thinner extensions of 
cytoplasm. 
Figure 8 Images of HAS2 distribution in fibroblast and epithelial cells. A) Phase contrast microscopy of MM1 
incubated with 100pg VEGF. B) Fluorescence microscopy of A after incubation with anti-HAS2 primary antibody 
and fluorescent secondary antibody.  C) Phase contrast microscopy of TR146 incubated with 10ng VEGF. D) 
Fluorescence microscopy of C after incubation with anti-HAS2 primary antibody and fluorescent secondary 
antibody. Note that all cells stained for HAS2 throughout the whole cell surface. 
A B 
C D 
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Cell Line EGF TGFβ1 VEGF 
HAS2 HAS3 HAS2 HAS3 HAS2 HAS3 
HACAT 0.757 0.826 -0.135 -0.119 0.333 -0.559 
PM1 0.363 -0.802 -0.164 -0.484 -0.597 -0.144 
TR146 0.977 0.959 0.595 0.035 -0.032 -0.124 
TYS -0.214 -0.612 0.874 -0.035 -0.310 -0.562 
MM1 0.954 0.694 -0.143 -0.341 -0.801 -0.314 
COMD11 0.113 0.825 -0.443 0.079 0.353 0.947 
COMD24 -0.863 -0.197 -0.312 -0.456 0.725 0.051 
COMD25 0.897 0.518 0.256 0.177 -0.556 0.096 
Table 7. Pearson’s Correlation Coefficient values between the concentration of growth factor added and 
the fluorescence intensity of HAS2 or HAS3 stain, calculated using ImageJ software; p=0.05 highlighted in 
dark green; p=0.1 highlighted in grey. 
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Effects of EGF 
The relative HAS2 and HAS3 levels in epithelial cells and fibroblasts grown under varied EGF 
levels are shown in Figures 9-12. The literature would suggest EGF promotes HAS2 and HAS3 
production in some epithelial and fibroblast lines. 
The data show a strong correlation (r=0.757) between EGF and HAS2 in the HACAT control 
line and a significant positive correlation (r=0.977) in TR146, which is consistent with the 
literature. However, this relationship is somewhat disturbed in PM1 and TYS cells. A similar 
situation is found with HAS3; HACAT and TR146 show strong positive correlations (r=0.826 
and r=0.959 respectively) while strong negative correlations are found in the other two cell 
lines. 
Regarding the fibroblast cell lines, a significant positive correlation (r=0.954) is found 
between EGF and HAS2 in the control MM1 line and in COMD25 cells. This is lost in COMD11 
and COMD24. The correlation with HAS3 levels is not as strong in the MM1 cells (r=0.694) 
but is nonetheless disturbed in COMD cell lines. 
Effects of TGFβ1 
Figures 13-16 show the relative HAS2 and HAS3 levels in epithelial cells and fibroblasts 
grown under varied TGFβ1levels. The literature suggests that TGFβ1decreases HAS2 and 
HAS3 production in some epithelial and fibroblast lines. 
The data here show no strong correlations of HAS2 or HAS3 with TGFβ1in the control HACAT 
cells. However, positive correlations occur in TR146 and TYS HAS2 levels (r=0.595 and 
r=0.874 respectively). This is not the expected relationship but may be another case of 
disturbed cell signalling pathways in transformed cells. 
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The control fibroblast line MM1 seems to undergo an increase of HAS2 and HAS3 at lower 
concentrations of TGFβ1followed by a decrease at higher concentrations. This relationship is 
conserved in some COMD cell lines and not in others. This is another case where signalling 
seems to be altered in tumour-associated cells. 
Effects of VEGF 
Figures 17-20 show the relative HAS2 and HAS3 levels in epithelial cells and fibroblasts 
grown under varied VEGF concentrations. The effects of VEGF on HAS expression have not 
been as well documented as those of EGF and TGFβ1. On increasing VEGF concentrations in 
epithelial cell cultures, HAS2 and HAS3 appeared to increase at low concentrations of VEGF 
and decrease at higher concentrations. 
VEGF showed a strong negative correlation (r=-0.801) with MM1 HAS2 levels, which was 
fairly conserved in the COMD cell lines. HAS3 increased at low VEGF concentrations and 
decreased at high VEGF concentrations in MM1 cells. However, this too was less 
pronounced, if not absent, in COMD cells. 
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Figure 9 HAS2 levels expressed in epithelial cells treated with different concentrations of EGF, measured by fluorescence 
intensity and run in duplicate. Please note that the data have been normalised separately within their experimental runs and 
are not relative to each other. A) HACAT cells B) PM1 cells C) TR146 cells D) TYS cells. There are positive correlations between 
EGF and HAS2 in the HACAT control line (A) and TR146 (C), which is consistent with the literature. This relationship is less  in 
PM1 and TYS cells (B and D).  
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Figure 10 HAS3 levels expressed in epithelial cells treated with different concentrations of EGF, measured by fluorescence 
intensity and run in duplicate. Please note that the data have been normalised separately within their experimental runs 
and are not relative to each other. A) HACAT cells B) PM1 cells C) TR146 cells D) TYS cells. HACAT and TR146 show positive 
correlations between increasing EGF and HAS3 while PM1 and TYS show negative correlations. 
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Figure 11 Relative HAS2 levels expressed in fibroblast cells treated with different concentrations of EGF, measured 
by fluorescence intensity and run in duplicate. A) MM1 cells B) COMD11 cells C) COMD24 cells D) COMD25 cells. 
There is a significant positive correlation between EGF and HAS2 in the control MM1 line (A) and in COMD11 cells 
(B). There is no correlation in COMD24 (C) and a negative correlation in COMD25 (D).  
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Figure 12 Relative HAS3 levels expressed in fibroblast cells treated with different concentrations of EGF, measured 
by fluorescence intensity and run in duplicate. A) MM1 cells B) COMD11 cells C) COMD24 cells D) COMD25 cells. The 
relationship between EGF and HAS3 levels is not consistent. A differential effect at low levels and high levels of EGF 
can be seen in MM1 (A) and COMD11 (B).  
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Figure 13 Relative HAS2 levels expressed in epithelial cells treated with different concentrations of TGFβ1, measured by 
fluorescence intensity and run in duplicate. A) HACAT cells B) PM1 cells C) TR146 cells D) TYS cells. There is no 
correlation evident in the HACAT cell line between TGFβ1 and HAS2. There are positive correlations in TR146 and TYS 
HAS2. This differs from the expected relationship reported in the literature (Pasonen-Seppänen., 2003). 
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Figure 14 Relative HAS3 levels expressed in epithelial cells treated with different concentrations of TGFβ1, measured by 
fluorescence intensity and run in duplicate. A) HACAT cells B) PM1 cells C) TR146 cells D) TYS cells. There is a positive 
correlation between TGFβ1 and HAS3 in the HACAT and TR146 cell lines. This is less consistent in PM1 and TYS. 
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Figure 15 Relative HAS2 levels expressed in fibroblast cells treated with different concentrations of TGFβ1, measured 
by fluorescence intensity and run in duplicate. A) MM1 cells B) COMD11 cells C) COMD24 cells D) COMD25 cells. 
There is generally an increase in HAS2 at low concentrations of TGFβ1 and less of an effect or even a decrease in 
HAS2 at higher concentrations of TGFβ1. 
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Figure 16 Relative HAS3 levels expressed in fibroblast cells treated with different concentrations of TGFβ1, measured 
by fluorescence intensity and run in duplicate. A) MM1 cells B) COMD11 cells C) COMD24 cells D) COMD25 cells. In 
MM1 cells, there is an increase of HAS3 at lower concentrations of TGFβ1 and a decrease at higher concentrations. 
However, this relationship is not consistent in COMD cell lines 
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Figure 17 Relative HAS2 levels expressed in epithelial cells treated with different concentrations of VEGF, 
measured by fluorescence intensity and run in duplicate. A) HACAT cells B) PM1 cells C) TR146 cells D) TYS cells. 
The general trend is an increase of HAS2 at low concentrations of VEGF and less effect or even a decrease of HAS2 
at higher concentrations. 
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Figure 18 Relative HAS3 levels expressed in epithelial cells treated with different concentrations of VEGF, 
measured by fluorescence intensity and run in duplicate. A) HACAT cells B) PM1 cells C) TR146 cells D) TYS cells. 
There appears to be an increase of HAS3 at lower concentrations and a decrease at higher concentrations, similar 
to the relationship seen with HAS2. However, the TYS cell line appears to only show a decrease in HAS3 levels. 
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Figure 19 Relative HAS2 levels expressed in fibroblast cells treated with different concentrations of VEGF, measured 
by fluorescence intensity and run in duplicate. A) MM1 cells B) COMD11 cells C) COMD24 cells D) COMD25 cells. 
VEGF showed a strong negative correlation with HAS2 levels in MM1. This was conserved in COMD25 but lost in the 
other COMD cell lines. 
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Figure 20 Relative HAS3 levels expressed in fibroblast cells treated with different concentrations of VEGF, measured 
by fluorescence intensity and run in duplicate. A) MM1 cells B) COMD11 cells C) COMD24 cells D) COMD25 cells. 
HAS3 increased at low VEGF concentrations and decreased at high VEGF concentrations in MM1 cells. This 
relationship was lost in COMD cell lines. 
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Summary of Growth Factor Effects 
These experiments have looked at the effects of growth factors individually, and the results 
frequently differ between tumour-associated cell lines and the epidermal control line, 
suggesting that signalling is altered or disturbed in tumour-associated cells. However, in vivo 
all these growth factors would be present simultaneously. When the data is put together it 
would seem that HAS2 synthesis is upregulated in epithelial cells. The positive effect of EGF 
may be conserved, while an inductive effect by TGFβ1 may be gained.  The effect of VEGF 
depends upon the levels found in the tumour. HAS3 levels in epithelial cells are subject to 
conflicting effects from different growth factors. It may be that HAS3 has a lesser role in cell 
signalling between transformed epithelial cells. 
No consistent patterns were seen in fibroblast HAS2 and HAS3 levels. The relationship seen 
in the MM1 control was usually changed by the growth factor but not in any predictable 
way. 
In summary, both fibroblasts and TR146 cells experience an increase in HAS2 expression 
(and sometimes HAS3) on addition of EGF. Conversely, TYS increased HAS2 expression on 
addition of TGFβ1.  Squamous Cell Carcinomas (SCC) undergo Epithelial to Mesenchymal 
Transition (EMT) as they become more advanced. This may be responsible for the varied 
responses seen in different epithelial tumour cell lines. Alternatively, this may be a case of 
convergent mutations, both leading to increased HA output.  
Quantitative HA Assay in Epithelial and Fibroblast Cells 
In order to determine whether changes in HA levels are proportional to changes in HAS 
levels, this experiment used the same epithelial cell (HACAT, PM1, TR146, TYS) and three 
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fibroblast cell lines (MM1, COMD25/11). Since the trends found in the ICC experiments were 
not always linear, two concentrations of EGF and VEGF were chosen to represent even non-
linear relationships. The epithelial cell lines were grown until at least 80% confluency before 
a 24 hour incubation with either EGF or VEGF. Two samples of confluent fibroblast cell lines 
were incubated with EGF and VEGF for 24 hours and 48 hours respectively. The conditioned 
medium was taken and spun down to remove any cells. An indirect sandwich hyaluronan 
assay was used to quantify short chain HA levels by measuring optical density (OD) at 
450nm and correcting these measurements against the background OD. Standard curves 
were produced in each assay, an example of which is shown in Figure 21. The results shown 
in Figures 22-23 show the HA quantities, calculated from the standard curves. 
 
HA in Epithelial Cell Lines 
All of the epithelial cell lines produced HA levels of more than 8.5ng/ml. However, the TYS 
and TR146 cell lines produced noticeably less than HaCaT. Interestingly, EGF and VEGF also 
gave different effects on HaCaT and PM1 lines, as opposed to TYS and TR146. 
Figure 21 Example HA standard curve 
calculated from set HA concentrations, 
measured in the same assay as the 
experimental data. Note that each data set 
therefore used a different standard curve. 
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In TR146 lines, HA increased on addition of EGF, as predicted by the increase in HAS2 levels, 
revealed by the fluorescent ICC. Conversely, the HaCaT, TYS and PM1 lines showed a 
decrease in HA levels despite a positive correlation between EGF and HAS2 levels. This could 
suggest another level of regulation affecting net HA production, such as catalytic activity of 
the enzyme, availability of substrate or increased degradation in the ECM. 
VEGF had a less clear role, possibly causing an increase in HAS2 and HAS3 at low 
concentrations and a decrease at high concentrations. Corresponding HA levels showed 
little change in HaCaT cells, a decrease on addition of growth factors in PM1 cells, an 
increase in TR146 and a mixed result in TYS. This would again suggest additional levels of 
regulation. 
HA in Fibroblast Cell Lines 
All the fibroblast lines produced more than 26ng/ml HA. Generally, there was less HA in 
samples taken at 48 hours than 24 hours. The exception seen in Figure 23 was not present in 
the duplicate assay so it was not reproducible.  
HA increased on addition of low concentrations of EGF in normal and tumour-associated 
fibroblasts. This corresponds to the increase in HAS2 seen in the ICC experiments. HA also 
increased on addition of low levels of VEGF, which corresponds to the increase in HAS3 seen 
in the ICC experiments. The trend in fibroblasts is that low levels of growth factors have 
larger effects than higher concentrations. This could be due to additional levels of regulation 
such as antisense RNA, which may be synthesised at high concentrations of HA. It is 
reported in the literature that TGFβ1 and EGF have optimum concentrations for eliciting 
peak HAS expression and peak migration (Grant, 1992).  The optimum concentration of 
TGFβ1 is consistently lower than that of EGF, so it may be that the optimum concentration 
of VEGF is similarly low.
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Figure 22 HA levels in epithelial cell lines as calculated from a standard curve derived from the same assay. All cell lines 
produced HA levels of more than 8.5ng/ml, although TYS showed lower levels than the control. HaCaT, PM1 and TYS 
lines showed a slight decrease in HA levels on addition of EGF and VEGF, whereas TR146 showed an increase in HA with 
both EGF and VEGF.  
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Figure 23 HA levels in fibroblast cell lines as calculated from a standard curve derived from the same assay. All the 
fibroblast lines produced more than 26ng/ml HA. HA levels were lower in samples taken at 48 hours compared to 24 
hours. The exception seen in MM1 with 100ng EGF was not present in the duplicate assay. HA levels increased in both 
normal and tumour-associated fibroblasts, on addition of low concentrations of EGF and VEGF. At higher 
concentrations, the effect was less. Also, EGF gave a stronger response than VEGF. 
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EMT Markers – Vimentin and E-Cadherin 
Having demonstrated changes in HA levels in the cultured stromal cells, this project will now 
attempt to determine its implications. It has been reported that HA levels are involved in 
Epithelial to Mesenchymal Transition (EMT), an important stage in tumorigenesis. In order 
to determine if EMT is taking place, the four epithelial cell lines were grown to confluency 
and incubated with decreasing concentrations of HA between 10μg and 10ng for 24 hours. 
The cells were then lysed and prepared for the SDS-PAGE protocol and subsequent Western 
blotting. The primary antibodies used were anti-vimentin and anti-E-cadherin. Vimentin is 
an intermediate filament present in mesenchymal cells whereas E-cadherin is an adhesive 
transmembrane protein present in epithelial cells.  
The PM1 cell line is unusual in that it does not express any E-cadherin but does express large 
quantities of vimentin, even in the HA-negative control. This could suggest it is not epithelial 
in the first place. 
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E-Cadherin expression was unchanged by increasing HA concentration. However, vimentin 
expression was switched on in TR146 on increasing HA concentration, which could be an 
early sign of EMT. 
 
Migration - Scratch Assays 
Scratch assays were carried out to look for increased cell motility. HaCaT, TYS and TR146 cell 
lines were grown to confluency; the monolayer was scratched with a blunt pipette tip, and 
the cells were monitored at 3 hours, 6 hours and 24 hours. Migration was quantified by 
looking at the amount of contacts where cells had moved into the scratch. Table 9 shows 
the scale used and examples of the histological appearance. 
 
 
  E-Cadherin  Vimentin 
Concentration 
HA (μg/ml) 
(kDa) 
0 0.01 0.1 1 10 
(kDa) 
0 0.01 0.1 1 10 
HaCaT 97 
 
57 
PM1 97 
 
57 
 
TYS 97 
 
57 
TR146 97 
 
57 
 
Table 8.  Western blots detecting E-Cadherin and Vimentin. PM1 does not show an epithelial 
phenotype profile. HACAT and TYS show no change on addition of HA. TR146 does not show any 
change in E-Cadherin expression but gains vimentin expression, which could indicate early EMT. 
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0% No closure 
   
20% <10 contacts 
40% 10-30 
contacts 
60% More area in 
contact than 
not 
80% Little 
evidence of 
the scratch 
remains 
100% No evidence 
of the 
scratch 
remains 
TYS SF 0hr (0%) TYS SF 6hr (40%) TYS SF 24 hr 
(100%) 
Table 9. Scale to quantify migration by percentage (left) and light 
microscopy images to show examples of a scratch, a contact and 
complete obliteration of the scratch (above). 
 
All of the epithelial lines migrated into the scratch to some extent. Table 10 shows the 
migration according to the scale above. HaCaT showed some contacts at 24 hours but there 
was no difference whether HA was present or not.  Similarly, TYS migrated into the scratch 
consistently and faster than HaCaT, but the addition of HA had no effect. TR146 migrated 
into the space consistently, even in the negative control, but this was noticeably faster than 
both TYS and HaCaT. Also, the addition of HA did increase the number of contacts seen at 3 
hours and 6 hours. 
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Sample Average Migration (%) 
Cell Line Added 
HA 
3 Hours 6 Hours 24 Hours 
HaCaT 
- 0 0 30 
10ng 0 0 20 
100ng 0 0 30 
1μg 0 0 40 
10μg 0 0 40 
TYS 
- 0 40 100 
10ng 0 40 100 
100ng 0 60 100 
1μg 0 60 100 
10μg 0 40 100 
TR146 
- 10 50 100 
10ng 30 70 100 
100ng 30 60 100 
1μg 70 90 100 
10μg 30 80 100 
Table 10. Average results of scratch assays run in duplicate. SCC cell lines TYS and TR146 migrated 
quicker than HaCaT. The addition of HA sped up the migration in TR146, but the effect on HaCaT 
and TYS was far less pronounced. 
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Chapter 4 Discussion 
Aims and Objectives 
This project aimed to identify the mechanisms and implications of increased HA synthesis in 
SCC. In order to identify the mechanisms of synthesis, this project has looked at which cell 
type is responsible, which HAS enzymes and which growth factors. As for the implications of 
HA synthesis, the literature suggests a link with EMT and migration, so this has been the 
focus of the second part of the project. 
A Note on Cell Lines 
Tumorigenesis is a hugely varied process, involving multiple mutations. These will involve 
different genes and have different causes, including both genetic and environmental risk 
factors, but ultimately lead to the same pathology. Such convergent mutations have been 
described in SCC previously (Boyle, et al., 2001) (India Project Team of the International 
Cancer Genome Consortium. , n.d.). For this reason, each carcinoma develops uniquely and 
we cannot expect cell lines from different tumours to behave exactly the same. The PM1 
cell line is taken from a dysplastic lesion from forehead skin and has consistently behaved 
differently to the TYS and TR146 cell lines. This could be due to its epidermal rather than 
mucosal origin. Alternatively, this may be because it is only dysplastic and still at an early 
stage in tumorigenesis; or perhaps if left untreated, this lesion was never going to become 
neoplastic. However, since its unusual characteristics cause us to question whether it is even 
epithelial, it will not be discussed further in this project.  
TYS and TR146 are both from well-differentiated, aggressive SCC, and both are metastatic. 
However, there have been many differences in behaviour, demonstrating how diverse 
mutations have led to similar phenotypes.  
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Distribution of HA Synthesis 
 It is well established that HA is synthesised at all surfaces of the cell membrane, and this 
was demonstrated again here in ICC experiments. All ICC samples stained for HAS2 and 
HAS3, whether fibroblast or epithelial, tumour-associated or not.  
Regarding distribution within the tumour, it would seem fibroblasts and some neoplastic 
epithelial cells are responsible for the increase in HA. The ICC results would suggest that this 
is primarily due to an increase in HAS2 on addition of exogenous EGF to the cells. In vivo, 
fibroblasts are responsible for stromal regulation. However, the assays carried out here 
showed similar levels of HA are produced by the epithelial cell lines. This may be a result of 
in vitro growth conditions where there is no stroma; epithelial cells have to form a 
basement membrane for themselves. It has been reported that epithelial cultures in vitro 
have lower expression of terminal differentiation markers and high expression of basal cell 
keratins (Freshney & Freshney, 2004). Perhaps an increase in HA output is also a 
characteristic of epithelial cells in culture. 
Mechanism of Increased HA Synthesis 
According to the ICC results, EGF caused an increase in HAS2 and HAS3 in HaCaT and TR146 
cells, but it was TGFβ1 that gave a similar response in TYS. Furthermore, the HA assay 
revealed that an increase in HA occurred on addition of EGF in TYS and TR146 but not 
HaCaT. This would suggest that HA expression is enhanced in transformed epithelial cells, 
but that different signalling pathways are affecting the different tumour cell lines. This 
would be an example of convergent mutations as described earlier.  
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It has been reported that VEGF only causes increased motility in oral SCC and not in normal 
fibroblast controls by phosphorylating Akt and activating the Akt pathway (Islam, et al., 
2014). The EGFR family is known to activate the Akt pathway amongst others (see Figure 7). 
One possible model is that EGF, TGF and VEGF are activating the Akt pathway, triggering 
increased HA synthesis and consequently cell motility.  
Since HaCaT shows an increase in HAS2/3 but a decrease in HA production, there must be 
additional levels of regulation. This may be for example decreased enzyme activity due to 
lack of phosphorylation or dimerisation; decreased availability of substrate; or an increase in 
turnover of HA by Hyals in the ECM. The literature reports that the expression of Hyals 
(Franzmann, 2003), MT-MMP1 (Nakamura, 2004) and ADAM proteases (which degrade 
CD44) is increased in head and neck SCC. However, it has been reported that more 
advanced tumours show decreased and/or irregular HA expression. Therefore, any model of 
HA regulation in the tumour must be dynamic, changing at different stages of 
tumorigenesis. 
HA synthesis increased in both MM1 and COMD lines on addition of low levels of growth 
factors, but not high levels. This differential response could explain why positive correlations 
in HAS2/3 synthesis were not seen in the ICC results. The signalling via EGF and VEGF 
pathways are likely to be normal signalling responses usually seen during wound healing. 
Implications of Increased HA Synthesis 
Successful EMT determines whether a cell experiences increased motility or gains the 
capacity for tissue invasion (Martin, et al., 2013). It requires the loss of E-cadherin, making 
the cell independent from contact growth inhibition. This is followed by the expression of 
matrix metalloproteinases, which allow the cell to break down stromal proteins and 
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membranes and increase adhesion. Only two markers were used here to demonstrate EMT. 
A positive result would require the loss of E-cadherin expression and a gain in vimentin. 
None of the cell lines showed this. Vimentin expression was switched on in TR146 and 
correlated with increasing HA levels. However, it retained E-Cadherin expression. This result 
may signify an early stage in EMT but it is not conclusive. Studies of EMT in SCC associate it 
with cell-cell dissociation and cell movement (Grille, 2003) (Boyer, et al., 2000). Since the 
Western blots were inconclusive, migration assays were run to look for evidence of EMT 
from its effects.  
Migration is movement on 2D surfaces without any obstructive stroma, as opposed to 
invasion, which involves the breakdown of the ECM (Kramer, 2013). A scratch assay shows 
collective 2D migration of epithelial sheets by means of EMT, and all epithelial cell lines 
were capable of this. HA signalling and motility is an important pathway in wound healing 
and angiogenesis, so this response may be normal physiology. However, TYS and TR146 
showed increased motility compared to HaCaT in the scratch assay. Furthermore, TR146 
migration was faster on addition of HA in increasing concentrations. Therefore, it is possible 
that HA might be involved in enhancing migration in some tumours. 
However, metastasis also requires invasive capabilities. A Boyden assay would show single-
cell 2D migration by means of chemotaxis through a membrane. The planned assay coated 
the membrane with collagen, so that a positive result would demonstrate invasion rather 
than simply migration (Kramer, 2013). The Boyden assays were abandoned due to the 
limited timespan of this project and since epithelial cell lines did not migrate well in work 
carried out by other researchers in the lab. However, this negative result may be significant 
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as this would indicate the cells have not gained invasive capabilities in the presence of HA 
signalling. More work needs to be carried out in this area to determine if this is the case. 
Limitations and Improvements 
By including epithelial and fibroblast cells, this project would look for heterotypic signalling. 
While these are the cell types most likely to be involved in HA signalling, there are other cell 
types found within the SCC that have not been considered, such as endothelial cells. 
The variety and quantity of growth factors present in the tumour microenvironment may be 
other areas of contention. In vivo no growth factor is present in isolation and the growth 
factors used in this study may have synergistic or contradictory effects. Further experiments 
using a test medium containing multiple growth factors may be more representative. Also, 
many of the ICC results showed differential effects on HAS2/3 expression at different 
quantities of growth factors. It may be helpful to measure the amount of growth factors 
produced by the different cell types during normal growth phases. This could then be used 
as a guide as to how much growth factor is present in the SCC. Also, only EGF, TGFβ1 and 
VEGF were used. Other growth factors such as PDGF and FGF-2 may also affect SCC 
signalling pathways. 
An obvious limitation of the study is that experiments were only run in duplicate. In the ICC 
results where the data was rarely statistically significant, extra data would make the 
conclusions drawn more reliable. 
ICC is an excellent method to localise proteins within a cell. However, its use for the 
quantification of proteins is not ideal. Many factors such as the confluency of samples and 
variations in incubation times and washes, will affect fluorescence intensity. This becomes 
particularly significant where fluorescence is very low or very high. While measures were 
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taken to normalise the data as much as possible, it will never be as accurate a quantification 
as a biochemical assay. 
When studying HA signalling, the most striking variable is the effect of HA chain length on 
signalling outcomes. The HA quantification assay used here detects HA of any length, but it 
would have been interesting to see which chain lengths were produced and if this changed 
on addition of growth factors. If the theory presented here is correct and HA is subject to 
increased turnover, perhaps a higher level of short chain HA fragments could be detected. 
Furthermore, when looking at the implications of increased HA levels, only a medium length 
chain HA was added to the media. This could be inappropriate if it were found that more 
short chain HA is produced in SCC. Since long chain HA is associated with tissue stability and 
cell integrity, and short chain HA is associated with inflammatory response and migration, it 
could be that the inappropriate addition of long chain HA is inhibiting migration.   
Conclusions 
The model proposed in this study is that EGF (and in some tumours TGFβ1) causes an 
increase in HAS2 expression in fibroblasts and transformed epithelial cells. A consequence 
of this is increased synthesis of HA and this is linked to the early signs of EMT and enhanced 
migration. Although this model is true of TR146, TYS behaved very differently. It is a possible 
explanation for the increase in SCC HA levels reported in the literature, but it is certainly not 
a consistent relationship in SCC. 
Further work in this field would include determining whether growth factors affect the 
production of HA proteases, exploring the role of different size HA chains in the tumour 
microenvironment; and to investigate invasive abilities of the epithelial cell lines using 
Boyden’s or similar assays. 
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Appendices 
Appendix 1 – Cell Culture Reagents 
10% FCS, 1% L-Glutamine MEM 
Foetal Calf Serum (Foetal Bovine Serum; Product 10270 Invitrogen; Product 41Q4025K 
Gibco) heat treated at 60c for 30-40min. 
Minimum Essential Medium Eagle 10x (MEM) (Product M-0275 Sigma): 
 150ml penicillin- streptomycin stabilised (Product P-4333 Sigma) 
 150ml MEM non-essential amino acid solution (Product M-7145 Sigma)  
 150ml sodium pyruvate (Product S-8636 Sigma) 
 33g sodium bicarbonate (Product S-8761Sigma) 
L-Glutamine 200mM stock (Product G-7513; Sigma) 
Medium Variations 
Additives: 
10mM β-Glycerophosphate (Product G6251 Sigma) 
100nM dexamethasone  (Product D1756 Sigma) 
50μg ascorbic acid (Product A7506 Sigma) 
 
Appendix 2 – ICC Antibodies 
HAS2 (H-60), Santa Cruz Cat No: Sc-66916 Lot No: G0109 Rabbit Polyclonal 
HAS3 (H-60), Santa Cruz Cat No: Sc-66917 Lot No: K2509 Rabbit Polyclonal 
Anti-Rabbit IgG conjugated with Alex Fluor 488, Cell Signaling Technology 
 Cat No: #4412 
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Appendix 3 – Statistical Formulae 
Corrected Total Cell Fluorescence (CTCF) 
CTCF = Integrated Density – (Area of selected cell X Mean fluorescence of background 
readings) 
Appendix 4 – ELISA Materials  
DuoSet Assay Development kit for Hyaluronan (#DY3614, R and D Systems) 
Wash Buffer:  PBS + 0.05% (v/v) Tween 20  (50µl per 100ml or 500µl of 10% 
Tween 20 per 100ml) - filtered 
Blocking Buffer:  PBS + 5.0% (v/v) Tween 20 (5ml per 100ml) + 0.05% Sodium azide 
(50mg per 100ml) - filtered 
Reagent Diluent: PBS + 5.0% (v/v) Tween 20 (5ml per 100ml) – filtered 
Stop Solution: 2N Sulphuric acid.  
Substrate solution: 1:1 mixture of colour reagent A (hydrogen peroxide) and B 
(tetramethylbenzidine) 
Streptavidin-HRP:  
Capture reagent: 0.5µg/ml Aggrecan (#842162) in PBS 
Detection reagent: 0.4µg/ml Aggrecan (#842163) in Reagent Diluent  
Standard Hyaluronan: HA (#842164) 
Appendix 5 – SDS PAGE and Western Blot Buffer Solutions 
RIPA buffer with Protease Inhibitors: 50mM Tris HCl pH 7.2,  
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 150mM NaCl 
 0.1% (w/v) SDS 
 1.0% (v/v) Triton x100 or 1% (v/v) NP40 
 1.0% (w/v) sodium deoxycholate 
 5mM EDTA 
 
Laemmli Loading Buffer:  62.5 mM Tris HCl pH 6.8 
 2% ((w/v)) SDS 
 25% ((v/v)) Glycerol 
 0.01% ((w/v)) Bromophenol Blue 
 5% ((v/v)) 2-Mercaptoethanol 
 
Laemmli Running Buffer (TGS):  25 mM Tris HCl pH 8.3 
 192 mM Glycine 
 0.1% ((w/v)) SDS 
 
Towbin Transfer Buffer: 5.82g  Tris 
 2.93g  Glycine 
 3.75ml 10% ((w/v)) SDS 
 200ml Methanol 
 to 1litre with dH2O 
 
Blocking Buffer: 100ml   1 x TBST 
 1g Dried milk powder 
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10 x TBST: 24.2g  Tris 
  80g Sodium chloride 
  5ml Tween 20  
  14ml Hydrochloric acid (adjust to pH 7.6) 
  to a total volume of 1 litre with dH2O 
10x TBS: as TBST without Tween 20  
 
